A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
Clinical trial NCT02734160 · COMPLETED
Trial details
- NCT number
- NCT02734160
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-15
- Primary completion
- 2018-08-02
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.